1. [Cyclic nucleotide phosphodiesterases: therapeutic targets in cardiac hypertrophy and failure].
- Author
-
Barthou A, Kamel R, Leroy J, Vandecasteele G, and Fischmeister R
- Subjects
- Humans, Animals, 3',5'-Cyclic-AMP Phosphodiesterases antagonists & inhibitors, 3',5'-Cyclic-AMP Phosphodiesterases metabolism, 3',5'-Cyclic-AMP Phosphodiesterases physiology, Myocytes, Cardiac drug effects, Myocytes, Cardiac metabolism, Molecular Targeted Therapy methods, Cyclic GMP metabolism, Cyclic GMP physiology, Signal Transduction drug effects, Signal Transduction physiology, Cyclic AMP metabolism, Cyclic AMP physiology, Phosphoric Diester Hydrolases metabolism, Phosphoric Diester Hydrolases physiology, Cardiomegaly drug therapy, Heart Failure drug therapy, Phosphodiesterase Inhibitors therapeutic use, Phosphodiesterase Inhibitors pharmacology
- Abstract
Cyclic nucleotide phosphodiesterases (PDEs) modulate neurohormonal regulation of cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple isoforms of PDEs with different enzymatic properties and subcellular locally regulate cyclic nucleotide levels and associated cellular functions. This organisation is severely disrupted during hypertrophy and heart failure (HF), which may contribute to disease progression. Clinically, PDE inhibition has been seen as a promising approach to compensate for the catecholamine desensitisation that accompanies heart failure. Although PDE3 inhibitors such as milrinone or enoximone can be used clinically to improve systolic function and relieve the symptoms of acute CHF, their chronic use has proved detrimental. Other PDEs, such as PDE1, PDE2, PDE4, PDE5, PDE9 and PDE10, have emerged as potential new targets for the treatment of HF, each with a unique role in local cyclic nucleotide signalling pathways. In this review, we describe cAMP and cGMP signalling in cardiomyocytes and present the different families of PDEs expressed in the heart and their modifications in pathological cardiac hypertrophy and HF. We also review results from preclinical models and clinical data indicating the use of specific PDE inhibitors or activators that may have therapeutic potential in CI., (© 2024 médecine/sciences – Inserm.)
- Published
- 2024
- Full Text
- View/download PDF